Uploaded July 2023 | Updated November 2026, 1 day ago
At Ending Age-Related Diseases 2022, Arkadi Mazin of Lifespan.io interviewed Dr. Yu Xuan Lu of the Max Planck Institute for Biology of Ageing on the uses of rapamycin. Rapamycin is likely to be the most well-established compounds associated with lifespan extension, and Dr. Lu discusses how and why the drug does what it does.
FOLLOW US
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
lifespan.io
facebook.com/lifespanio
instagram.com/lifespan.io
HOW CAN YOU SUPPORT US?
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
Lifespan.io, a 501(c)(3) nonprofit organization.
► Support us with monthly donations by becoming a Lifespan Hero: lifespan.io/hero
► Subscribe: youtube.com/user/LifespanIO
► Learn more, and help us: lifespan.io
#longevity #aging #mtor
At Ending Age-Related Diseases 2022, Arkadi Mazin of Lifespan.io interviewed Dr. Yu Xuan Lu of the Max Planck Institute for Biology of Ageing on the uses of rapamycin. Rapamycin is likely to be the most well-established compounds associated with lifespan extension, and Dr. Lu discusses how and why the drug does what it does.
FOLLOW US
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
lifespan.io
facebook.com/lifespanio
instagram.com/lifespan.io
HOW CAN YOU SUPPORT US?
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
Lifespan.io, a 501(c)(3) nonprofit organization.
► Support us with monthly donations by becoming a Lifespan Hero: lifespan.io/hero
► Subscribe: youtube.com/user/LifespanIO
► Learn more, and help us: lifespan.io
#longevity #aging #mtor










